We analysed the treatment outcome of primary refractory HD patients managed with high-dose chemotherapy and haematopoietic cell transplantation. Data of 65 adult patients who underwent HDC/ASCT in nine Polish centres for primary resistant Hodgkin's disease between June 1991 and July 2000 were collected retrospectively. Response rate to HDC/ASC: CR, 54%; PR, 20%; less than PR, 15%; early deaths, 11%. Actuarial 3-year OS and PFS were 55% and 36%, respectively. In multivariate analysis, lack of bulky lymph nodes and use of immunotherapy were favourable factors for both OS and PFS. IPF Ͻ3 at the time of transplantation was predictive for PFS. However, the prognostic impact of immunotherapy should be interpreted with caution since this group included more patients who achieved CR after HDC/ASCT. The results of HDC/ASCT are encouraging and confirm earlier findings. The role of immunotherapy should be further investigated in prospective trials.
occasionally. 3, 4 For selected patients, salvage radiation therapy may be considered as an alternative option if the patient has not been previously irradiated. 5 Recently, encouraging reports on high-dose chemotherapy with autologous stem cell transplantation (HDC/ASCT) in this group of patients have been published by European and American institutions, but randomised trials comparing this treatment with standard therapy are still lacking. [6] [7] [8] [9] [10] At present, autologous bone marrow transplantation procedures are performed in adult patients in 11 centres in Poland. Data from nine of them, which were active before 1999, were collected retrospectively and analysed in the current study. The aim of the study was to evaluate treatment results and prognostic factors in univariate and multivariate models for overall and progression-free survival.
Patients and methods
Data of 65 adult patients who underwent HDC/ASCT for primary resistant Hodgkin's disease between June 1991 and July 2000 were collected retrospectively. Eligibility criteria for this study included: disease progression during first-line chemotherapy, or partial remission after induction treatment with progression within 3 months of completion of treatment. Patients with persistent scan abnormalities without local progression or residual disease in other sites were not considered to be primary resistant. Clinical data were collected until September 2000. Out of the initial 100 records received, we identified 65 which strictly fulfilled the above criteria. Data of the remaining 35 patients were excluded due to lack of evidence of disease progression within the specified period of 3 months after first-line treatment. In January 2001, records of all these patients were reviewed and reporting centres were contacted to provide additional information and follow-up. The median follow-up period was 26 months (range: 5-115 months). Patient characteristics at presentation, initial therapy, transplantation, and details of high-dose therapy are presented in Tables 1-3. Prognosis was assessed using the International  Prognostic Factors score on advanced Hodgkin disease  (IPF), proposed by Hasenclever and Diehl. 11 Thirty-five patients received involved or extended field radiotherapy before HDC/ASCT, and four were irradiated as consolidation of HDC/ASCT. No grafts were manipulated in vitro. Thirty-eight percent of patients received haematopoietic growth factors. The response was usually assessed 1 month after completion of chemotherapy. Physical examination, plain X-ray and computed tomography scanning were routinely used for response evaluation. Gallium scintigraphy and magnetic resonance imaging were used in selected cases. Partial remission was defined according to WHO criteria. A complete remission group also included patients with persistent scan abnormalities without biopsy confirmation (complete remission uncertain).
Four patients received involved field radiotherapy after HCD/ASCT. Eighteen patients in two centres received immunotherapy as part of running protocols: 14 patients received recombinant interferon ␣ 3 ϫ 10 6 U/day s.c. every other day for 1 month. The dose was then escalated to 3 ϫ 10 6 U/m 2 s.c. every other day for 5 months. Four patients were treated with recombinant interleukin-2, 6 ϫ 10 6 U/m 2 daily for 1 week. After a 2-week interval, interleukin-2 was given at the same dose concomitantly with recombinant interferon ␣ 3 ϫ 10 6 U/day for 4 weeks (20 doses). Finally, after a 4-week interval, interferon ␣ was administered three times a week for 6 months at a dose of 3 ϫ 10 6 U. The remaining patients received no consolidation treatment after transplantation.
Statistical methods
Median follow-up time was calculated as proposed by Schemper et al. 12 Analysis of overall (OS) and progressionfree survival (PFS) was performed with the Kaplan-Meier Table 5 Significant prognostic factors for OS after HDC/ASCT 
Results
A total of 48 patients (74%) responded to high-dose chemotherapy, including 35 (54%) in CR and 13 (20%) in PR. With a median follow-up of 26 months, probabilities of OS and PFS at 3 years are 55% (95% CI: 41-69%) and 36% (95% CI: 23-50%), respectively (Figure 1) .
On univariate analysis, four factors were found to influence OS and PFS: IPF у3 at the time of diagnosis (P ϭ 0.02 and P ϭ 0.05) and transplantation (P Ͻ 0.01 and P ϭ 0.05), immunotherapy as a part of HDC/ASCT (P ϭ 0.04 and P Ͻ 0.01) and lymph node diameter of Ͼ5 cm at the time of transplantation (P Ͻ 0.01 and P ϭ 0.04) ( Tables 4 and 5 ). The assessment of IPF at the time of diagnosis was possible for only a subgroup of patients and therefore this variable was not included in the multivariate analysis. Immunotherapy (P Ͻ 0.01), lymph node diameter Ͼ5 cm (P Ͻ 0.01) and IPF у3 at the time of transplantation (P Ͻ 0.01) remained significant for PFS on multivariate analysis for PFS. OS was influenced only by immunotherapy (P Ͻ 0.01) and lymph node diameter at transplantation (P Ͻ 0.01). The group of patients treated with immunotherapy included significantly more patients who achieved CR after HDC/ASCT (P ϭ 0.04, Fisher's exact test). In the group of patients receiving immunotherapy, an analysis of the subgroup treated with recombinant interferon ␣ alone vs recombinant interleukin-2 and recombinant interferon ␣ was not possible due to the small number of patients treated.
There were eight (11%) transplant-related deaths (seven early and one late, 6 months after transplantation). Infection was the most common cause of treatment-related death. Additionally, one fatal interstitial pneumonitis was observed. No cases of secondary malignancy were reported.
Discussion
The outcome of patients who presented with early treatment failure and were managed with standard-dose salvage chemotherapy is poor. In the report of Longo et al, 13 the median survival of 51 patients was 16 months and no patient was alive at 8 years. Consistent results were presented by Bonfante et al 4 in a group of patients refractory to alternating MOPP/ABVD. In contrast, results of HDCT/ASCT seem to be more promising. In our group of 65 patients, the 3-year OS and PFS were 55% and 36%, respectively. In a group of 122 HD patients, Lazarus et al 8 reported 50% and 38% patients remaining alive and without progression 3 years from the salvage HDC/ASCT. Moreover, other published results of HDC/ASCT on larger series of patients demonstrated a potential benefit from HDC in primary resistant Hodgkin's disease (Table 6 ). However, the actual benefit of the treatment can be overestimated due to selection bias. Recently, Jostings et al 5 showed that the majority of primary resistant patients receiving salvage therapy were excluded from high-dose programmes due to progressive disease, life-threatening severe toxicity of conventional treatment or age above 60 years. According to this study, only 33% of patients reported in the database of the German Hodgkin's Lymphoma Study Group received HDC/ASCT. There are no randomised clinical trials confirming the value of high-dose chemotherapy in this highly selected group of patients. Thus, the benefit of HDC/ASCT may be estimated only through case-matching with historical controls. 7, 14 In the group from the Stanford study there was no difference in OS at 4 years, but the advantage of the high-dose group was evident in freedom from progression probability (FFP, 52% vs 19%, P ϭ 0.01) and event-free survival (EFS, 52% vs 19%, P ϭ 0.01).
14 In the French study, the 6-year overall survival from diagnosis was 38% for grafted patients and 29% for patients treated conventionally (P ϭ 0.058). At present it is clear that a considerable proportion of patients with primary resistant Hodgkin's disease can be successfully treated with high-dose treatment, but the outcome in individual series is highly influenced by the distribution of risk factors. There are several variables considered to be of prognostic relevance in previous autotransplantation studies: performance status at transplantation, resistant disease at transplantation, number of unsuccessful conventional chemotherapy regimens, B symptoms at relapse, stage, age, bone marrow involvement, relapse in previous radiation therapy fields, extranodal disease at relapse, extensive pulmonary involvement, elevated serum lactate dehydrogenase and male sex. 5, 6, [8] [9] [10] [15] [16] [17] [18] [19] [20] [21] [22] In primary progressive Hodgkin's disease, failure to attain even temporary remission was also identified as an adverse prognostic factor for OS. 5, 10 Of the variables analysed in the present study, bulky lymph nodes at transplantation and immunotherapy following HDC/ASCT were predictive for both OS and PFS, and the IPF score at transplant was predictive for PFS. The importance of bulky disease at the time of transplantation has been reported by numerous authors. 5, 9, 16, [20] [21] [22] The role of maintenance immunotherapy after first-line treatment is controversial and no welldesigned phase III trials addressing this issue have been conducted in HD patients. Aviles et al 23 suggested the benefit of maintenance therapy with interferon ␣ in complete responders after induction treatment. In this study, a substantial improvement in favour of immunotherapy was observed both for overall and disease-free survival (OS, 33 Table 6 Results of larger autotransplantation series in patients refractory to induction treatment 92% vs 67%; DFS, 91% vs 58%). A possible role of recombinant human interleukin-2 given concomitantly with interferon ␣ to control minimal residual disease after HDC/ASCT was reported by Nagler et al. 24 The survival probability at 48 months for HD patients receiving immunotherapy was 100% as compared to 57% in historical controls who did not receive immunotherapy (P Ͻ 0.02). In an interim analysis of a prospective study, the authors observed that OS and DFS rates at 48 months were higher for HD patients who had received interleukin-2 and interferon ␣ than for the controls (88% and 84% vs 78% and 54%). 25 In our study, the benefit of immunotherapy may have been influenced by a selection bias -a much higher rate of complete responders to primary chemotherapy was noted in this group.
The factor that has not been analysed in previous HDC/ASCT studies, was the International Prognostic Factors Project score (IPF) on Advanced Hodgkin's Disease. 11 This system includes some parameters demonstrated to be of significance in previous autotransplantation studies: age, sex and stage. Unfortunately, in our series complete data at diagnosis were available in only 43 out of 65 patients and could not be included in multivariate analysis. Surprisingly, among 43 patients resistant to induction treatment with complete data at diagnosis, only 19 (44%) had three or more risk factors and could be included in a 'high-risk' group. We confirm the suggestion of other authors that only a proportion of high-risk patients can be identified based on this scoring system. 26 The present data and studies of others indicate that HDC/ASCT may be of therapeutic value in HD refractory to induction treatment. Similar to other observations, we found bulky disease to be an adverse prognostic factor for HDC/ASCT outcome. We also observed that the IPF scores at the time of transplantation can help predict the results of high-dose treatment. The addition of immunotherapy with interferon, with or without interleukin 2, to HDC/ASCT may improve these results in refractory HD patients.
